NCT01277692View on ClinicalTrials.gov

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 3, 2010

Primary Completion Date

May 9, 2011

Study Completion Date

May 9, 2011

Conditions
Hepatitis C
Interventions
DRUG

GSK2336805 10mg

single dose once daily

DRUG

GSK2336805 30mg

single dose once daily

DRUG

GSK2236805 100mg

single dose once daily

DRUG

GSK2236805 200mg

single dose once daily

DRUG

GSK2236805 10mg

repeat dose once daily for 7 days

DRUG

GSK2236805 dose to be determined up to 100mg

repeat dose once daily for 7 days

DRUG

GSK2236805 5mg

single dose in HCV infected patients

DRUG

GSK2236805 30mg

single dose in HCV infected patients

DRUG

GSK2236805 100mg

single dose in HCV infected patients

Trial Locations (3)

66219

GSK Investigational Site, Lenexa

91911

GSK Investigational Site, Chula Vista

08046

GSK Investigational Site, Willingboro

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY